H2020Индивидуална стипендия2019–2021

DaPhNIs · Role of the Maternal Gut Microbiota in Immune Activation at the Maternal-Foetal Interface: Impact on Preeclampsia and Offspring's Immune Development

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2019-07-16 → 2021-07-15
Финансиране от ЕС: 168 277 €
Участници: 1
Схема: MSCA-IF-EF-SE

Линиите свързват координатора с партньорите.

Накратко на български

Черевните бактерии на майката и влиянието им върху имунната система при прееклампсия се проучват чрез модели с мишки и човешки данни. Това помага за откриването на нови биомаркери и механизми за подобряване на здравето на майката и бебето.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Role of the Maternal Gut Microbiota in Immune Activation at the Maternal-Foetal Interface: Impact on Preeclampsia and Offspring's Immune Development

The main goal of the DaPhNIs project is to investigate how changes in gut microbiota during pregnancy impact immune responses at the maternal-foetal interface (MFI), and to determine the consequences on pregnancy outcomes as well as development of offspring’s immunity. Gut microbiota is an ecological community of commensal, symbiotic and pathogenic microorganisms, with a fundamental role in the maintenance of the host immune homeostasis. Accordingly, changes in the variety and composition of the host gut microbiota - a phenomenon termed “dysbiosis” - affect systemic immune responses and can disrupt the balance between pro- and anti-inflammatory activation leading to pregnancy-related diseases such as preeclampsia. In the DaPhNIs project we aim to investigate the immunological and molecular mechanisms through which changes in gut microbiota impact pregnancy outcome and fetal growth. Translational relevance of findings specifically to preeclampsia will be evaluated in a large cohort of patients, with implications potentially arising from the identification of novel biomarkers and of molecular mechanisms amenable to pharmacologic intervention. To test this hypothesis, three different aims were pursued: 1. Determine how maternal dysbiosis affects phenotype and activation of B cells at the MFI, and the consequences on pregnancy outcome in a C57/BL6 murine model. 2. Determine how maternal dysbiosis affects maternal-foetal transfer of cells, and the consequences on development and function of the neonatal immune system in a C57/BL6 murine model. 3. Identify novel human biomarkers for preeclampsia.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Preeclampsia is a leading cause of morbidity and mortality in pregnancy. Although the pathogenesis remains largely elusive, it is thought to reside in loss of immune-tolerance at the maternal-foetal interface. At present, preeclampsia can neither be reliably predicted nor prevented. Scope of this research project is to investigate how changes in microbiota during pregnancy impact immune responses at the maternal-foetal interface, and to determine the consequences on pregnancy outcomes as well as development of offspring’s immunity. Translational relevance of findings specifically to preeclampsia will be evaluated in a large cohort of patients, with implications potentially arising from the identification of novel biomarkers and of molecular mechanisms amenable to pharmacologic intervention.The Experienced Researcher (ER) of this study, Dr. Silvia Giugliano, is an accomplished immunologist with primary expertise in organ-specific immune responses to microbes. Formerly an independent academic researcher in the USA, she was recently recruited to work at the European Institute of Oncology (Milan, Italy) by Prof. Maria Rescigno, a world-class expert in the field of microbiota and mucosal immunity, specifically to advance the hosting laboratory’s expertise in placental immunity. There is an urgent call for actions aimed at improving women’s health, and it is incumbent on the scientific community to tackle this issue. Thus, the present proposal captures the current zeitgeist and social responsibility of Science. Complementary, prime expertise between the ER and host laboratory will create a synergistic enterprise, ideally suited to the pursuit of this ambitious research goal. Findings and hypotheses generated in this process will kick off additional, related projects, and will be disseminated beyond the boundaries of the scientific community and to public audiences. The ER will emerge with new skills, and the capability to transition to independence in her home country.

Оригинален текст от CORDIS (на английски).

Участници

HUMANITAS MIRASOLE SPA · Rozzano (Mi)КоординаторИталия